Monitoring for Creutzfeldt-Jakob Disease in people who received human growth hormone
Official title: CREUTZFELDT-JAKOB DISEASE SURVEILLANCE IN RECIPIENTS OF HUMAN GROWTH HORMONE
Funded at Westat, INC. · NIH-11128313 · Data updated 2026-11-12
This study is looking at whether people who have received human growth hormone treatments might be more likely to develop Creutzfeldt-Jakob Disease, a rare brain condition, so we can better understand the safety of these treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Westat, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $252,785 |
| NIH project number | 75N94023F00090-P00001-0-1 |
| Project ID | NIH-11128313 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received human growth hormone therapy.
✕Less likely to help
Patients who have never received human growth hormone or those with pre-existing neurological conditions unrelated to CJD may not benefit from this research.
What this research studies
This research focuses on tracking the occurrence of Creutzfeldt-Jakob Disease (CJD) in individuals who have received human growth hormone (hGH) treatments. The study aims to gather data on potential links between hGH administration and the development of CJD, a rare but serious neurodegenerative condition. By analyzing patient health records and conducting surveillance, the research seeks to identify any patterns or cases of CJD among these patients. This information could help improve safety protocols and inform future treatment guidelines for hGH recipients.
Why it matters
Potential benefit: If successful, this research could enhance the safety of human growth hormone treatments by identifying risks associated with CJD.
How similar studies have gone: Previous research has indicated potential risks associated with human growth hormone, making this surveillance approach both relevant and necessary.
Where this research is happening
-
Westat, INC.
Rockville, United States Active
Researchers
- Principal investigator: Martier, Karen — Westat, INC.
- Study coordinator: Martier, Karen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.